Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy.


Journal Article

BACKGROUND:The development of a microcomputer-based device permits quick, simple, and noninvasive quantification of the respiratory sinus arrhythmia (RSA) during quiet breathing. METHODS AND RESULTS:We prospectively and serially measured the radionuclide left ventricular ejection fraction and the RSA amplitude in 34 cancer patients receiving up to nine monthly bolus treatments with doxorubicin hydrochloride (60 mg/m2). Of the eight patients who ultimately developed symptomatic doxorubicin-induced congestive heart failure, seven (87.5%) demonstrated a significant decline in RSA amplitude; five of 26 subjects without clinical symptoms of cardiotoxicity (19.2%) showed a similar RSA amplitude decline. On average, significant RSA amplitude decline occurred 3 months before the last planned doxorubicin dose in patients destined to develop clinical congestive heart failure. CONCLUSION:Overall, RSA amplitude abnormality proved to be a more specific predictor of clinically significant congestive heart failure than did serial resting radionuclide ejection fractions.

Full Text

Duke Authors

Cited Authors

  • Hrushesky, WJ; Fader, DJ; Berestka, JS; Sommer, M; Hayes, J; Cope, FO

Published Date

  • August 1991

Published In

Volume / Issue

  • 84 / 2

Start / End Page

  • 697 - 707

PubMed ID

  • 1860214

Pubmed Central ID

  • 1860214

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

International Standard Serial Number (ISSN)

  • 0009-7322

Digital Object Identifier (DOI)

  • 10.1161/01.cir.84.2.697


  • eng